Literature DB >> 8209865

Bcl-2 rearrangement in Hodgkin's disease and reactive lymph nodes.

N Corbally1, L Grogan, M M Keane, D M Devaney, P A Dervan, D N Carney.   

Abstract

The chromosomal translocation t(14;18)(q32;q21), which involves the bcl-2 oncogene, occurs in most follicular lymphomas. Recent evidence suggests that this translocation occurs in Hodgkin's disease, linking its cellular origin and oncogenesis to follicular non-Hodgkin's lymphomas. Using polymerase chain reaction, the authors examined both Hodgkin's disease (n = 60) and reactive lymph nodes (n = 34) for the presence of bcl-2/JH breakpoint fragments, which are indicative of the t(14;18) chromosomal translocation in the major breakpoint region of the bcl-2 gene. The translocation was detected in approximately 10% of both Hodgkin's disease and nonmalignant reactive lymph node cases. These results suggest the possibility that the translocation may occur in the reactive component of Hodgkin's disease and not in the putative malignant cells, the Reed-Sternberg cells. Furthermore, the detection of the translocation in reactive lymph nodes suggests that it may not be the primary factor in the oncogenesis of follicular lymphoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8209865     DOI: 10.1093/ajcp/101.6.756

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

Review 1.  Chromosomal translocations among the healthy human population: implications in oncogenesis.

Authors:  Mridula Nambiar; Sathees C Raghavan
Journal:  Cell Mol Life Sci       Date:  2012-09-05       Impact factor: 9.261

2.  Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas.

Authors:  P Soubeyran; I Hostein; M Debled; H Eghbali; I Soubeyran; F Bonichon; T Astier-Gin; B Hoerni
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

3.  Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival.

Authors:  D Ofner; K Riehemann; H Maier; B Riedmann; H Nehoda; M Tötsch; W Böcker; B Jasani; K W Schmid
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.